Figure 5 Treatment with disease‐modifying drugs (DMDs) as a proportion of patients treated at each level of Expanded Disability Status Scale (EDSS). DMDs include IFNβ‐1a (avonex), IFNβ‐1b (betaferon, rebif) and glatiramer acetate (copaxone). The Belgian sample at EDSS 3 appears as an outlier with low DMD treatment but potentially high relapse frequency, translating into low work capacity (fig 2), low utility (fig 6) and high costs.